Review the main clinical trials

Explore the most recent randomised controlled trial data investigating the efficacy and safety of
anticoagulation therapy in patients with cancer-associated venous thromboembolism (VTE) using
the links below. The impact of these trials on current clinical practice will be presented by
Professor Agnelli and discussed by our expert faculty, so you may find it useful to familiarise
yourself with the studies ahead of the meeting:

CARAVAGGIO

Agnelli A, et al. N Engl J Med 2020;382:1599–607.

The multinational, randomised, investigator-led, open-label, non-inferiority CARAVAGGIO trial compared apixaban and dalteparin in cancer patients with symptomatic or incidental acute proximal deep-vein thrombosis or pulmonary embolism over 6 months.

ClinicalTrials.gov number NCT03045406

Go to Details

SELECT-D

Young AM, et al. J Clin Oncol 2018;36:2017–23.

The multicentre, randomised, open-label SELECT-D trial compared dalteparin and rivaroxaban in patients with active cancer who had symptomatic or incidental pulmonary embolism, or symptomatic lower extremity proximal deep-vein thrombosis.

Go to Details

HOKUSAI

Raskob GE, et al. N Engl J Med 2018;378:615–24.

The open-label, non-inferiority HOKUSAI trial compared edoxaban and dalteparin in patients with cancer who had acute symptomatic or incidental VTE.

ClinicalTrials.gov number NCT02073682

Go to Details

Access the latest guidance

Explore the latest guidelines for the treatment of VTE in patients with cancer.

These guidelines will be discussed by our expert faculty, so you may find it useful to familiarise yourself
with them ahead of the meeting:

ASH guideline for management of venous thromboembolism: prevention and treatment in patients with cancer

The American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer were published in February 2021. They incorporate the latest data into their recommendations and will be discussed throughout the webinar.

Go to Details

CHEST guideline and expert panel report on antithrombotic therapy for VTE disease

The antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report was published in August 2021. This guideline and report are compiled from up-to-date evidence including the recent CARAVAGGIO trial.

Go to Details

Hear from some of the faculty

Dr Colin Church

University of Glasgow, UK

For those of you attending the webinar scheduled for audiences from Europe and the Americas, I am looking forward to sharing with you my perspectives as a pulmonologist. During this live, interactive discussion of a clinical-case scenario involving a patient with cancer and VTE, we will be debating various patient- and treatment-related factors that can pose practical challenges to the management of anticoagulation in patients with active cancer. The faculty and I will also share our experiences of how we have addressed these challenges in clinical practice as part of a multidisciplinary approach.

Dr Jean Connors

Brigham and Women's Hospital and Dana-Farber Cancer Institute Boston, MA, USA

Patients with cancer who suffer a VTE are some of the most challenging patients that we deal with in our anticoagulation clinic. A low level of VTE risk awareness among these patients may delay diagnosis, further complicating the challenges of managing their increased risk of VTE recurrence and bleeding, compared with the non-cancer patients that we see. Until recently, we have been managing these patients with low molecular weight heparin, but data have recently become available that show us that for many patients with cancer associated VTE, DOACs overcome the burdens associated with the use of the standard of care LMWH. I look forward to discussing the challenges in treating patients with cancer associated thrombosis, and the opportunities to improve the management of VTE in this unique patient population.

Prof Andrés Muñoz Martin

Complutense University Madrid, Spain

I am excited to be facilitating the interactive discussion, which will focus on a variety of common challenges and considerations for our clinical-case scenario of a patient with cancer who experiences VTE. We will explore the patient journey from the initiation of anticoagulation through to the duration of continued therapy, and asking the multidisciplinary panel to provide their expert perspectives on a variety of clinical challenges. I look forward to receiving your questions during what I expect to be a highly informative session, so that we may share our specific experiences with you.

Prof. Giancarlo Agnelli

University of Perugia, Italy

It is my pleasure to be chairing this insightful meeting focusing on the management of anticoagulation therapy in this challenging patient population. I look forward to discussing the latest clinical evidence and guideline recommendations on the use of DOACs in patients with cancer and VTE, and how we can apply them in clinical practice.

Prof. Masataka Ikeda

Hyogo College of Medicine Nishinomiya, Japan

For those of you attending the webinar from the Asia-Pacific region, I look forward to you joining my colleagues and me for the interactive clinical-scenario discussion. During this session, we will be applying the latest evidence and guidelines presented during the opening sessions, exploring what more can be learned from these studies, and hearing expert perspectives from the multidisciplinary panel. I am sure that this session will provide you with greater insight into the unique considerations around anticoagulation management for these patients.

Technical meeting guidance

To ensure you have the best experience at the webinar, please consider the following:

You can join the meeting from a computer (using any browser), mobile or tablet – whichever works best for you

Try to watch from a quiet place

Please ensure that you have your virtual private network (VPN) turned off

Once the meeting has started, you can select your language from the drop-down menu that appears on-screen

Check your internet connection before the meeting

Throughout the meeting, send in your questions for the faculty